Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

caricotamide/tretazicar

A combination therapy consisting of the prodrug tretazicar and the enzyme co-substrate caricotamide with potential antineoplastic activity. In the presence of separately and simultaneously administered caricotamide, tretazicar is converted to the short-lived cytotoxic DNA cross-linking agent dinitrobenzamide by NAD(P)H quinine oxidoreductase 2 (NQO2), resulting in the inhibition of DNA replication and the induction of apoptosis. NQO2 has been found to be elevated in certain cancers such as hepatocellular carcinoma (HCC).
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
US brand name:Prolarix
Code name:EP-0152R/CB1954
Chemical structure:1-carbamoylmethyl-3-carbamoyl-1,4-dihydropyridine/5-(aziridin-1-yl)-2,4-dinitrobenzamide
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search